1. Home
  2. GRFS vs OBDC Comparison

GRFS vs OBDC Comparison

Compare GRFS & OBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRFS
  • OBDC
  • Stock Information
  • Founded
  • GRFS 1940
  • OBDC 2015
  • Country
  • GRFS Spain
  • OBDC United States
  • Employees
  • GRFS 23737
  • OBDC N/A
  • Industry
  • GRFS Biotechnology: Pharmaceutical Preparations
  • OBDC Investment Managers
  • Sector
  • GRFS Health Care
  • OBDC Finance
  • Exchange
  • GRFS Nasdaq
  • OBDC Nasdaq
  • Market Cap
  • GRFS 5.5B
  • OBDC 6.0B
  • IPO Year
  • GRFS 2006
  • OBDC 2019
  • Fundamental
  • Price
  • GRFS $8.05
  • OBDC $15.10
  • Analyst Decision
  • GRFS Sell
  • OBDC Hold
  • Analyst Count
  • GRFS 2
  • OBDC 8
  • Target Price
  • GRFS $10.50
  • OBDC $15.43
  • AVG Volume (30 Days)
  • GRFS 1.3M
  • OBDC 1.9M
  • Earning Date
  • GRFS 01-01-0001
  • OBDC 11-06-2024
  • Dividend Yield
  • GRFS N/A
  • OBDC 9.82%
  • EPS Growth
  • GRFS N/A
  • OBDC N/A
  • EPS
  • GRFS 0.27
  • OBDC 1.61
  • Revenue
  • GRFS $7,814,096,584.00
  • OBDC $1,613,593,000.00
  • Revenue This Year
  • GRFS $8.86
  • OBDC $2.78
  • Revenue Next Year
  • GRFS $7.00
  • OBDC $11.69
  • P/E Ratio
  • GRFS $35.12
  • OBDC $9.36
  • Revenue Growth
  • GRFS 7.21
  • OBDC 6.06
  • 52 Week Low
  • GRFS $5.30
  • OBDC $13.98
  • 52 Week High
  • GRFS $12.15
  • OBDC $16.91
  • Technical
  • Relative Strength Index (RSI)
  • GRFS 51.40
  • OBDC 46.57
  • Support Level
  • GRFS $7.29
  • OBDC $15.03
  • Resistance Level
  • GRFS $7.85
  • OBDC $15.45
  • Average True Range (ATR)
  • GRFS 0.33
  • OBDC 0.16
  • MACD
  • GRFS 0.06
  • OBDC -0.03
  • Stochastic Oscillator
  • GRFS 77.22
  • OBDC 14.58

About GRFS Grifols S.A.

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.

About OBDC Blue Owl Capital Corporation

Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.

Share on Social Networks: